@phdthesis{Roth2021,
  author    = {Roth, Patrick},
  title     = {Metalltricarbonyl-basierte CO-releasing molecules (CORMs): Variation der Freisetzungskinetik und Biokonjugation},
  doi       = {10.25972/OPUS-24017},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240171},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Kohlenstoffmonoxid ist ein wichtiges kleines Signalmolek{\"u}l das im menschlichen K{\"o}rper durch die enzymatische Wirkung von H{\"a}m-Oxygenase (HO) auf H{\"a}m produziert wird. F{\"u}r eine thera-peutische Anwendung werden Metallcarbonyl-Komplexe als CO-releasing molecules (CORMs) untersucht, die eine kontrollierte Freisetzung in biologischen Zielstrukturen erlauben. Daf{\"u}r wird entweder die Ligandenperipherie ("drug sphere") modifiziert oder die CORMs an bio-molekulare Tr{\"a}gersysteme konjugiert. Im Rahmen dieser Arbeit stand dabei die lichtinduzierte Freisetzung von Kohlenstoffmonoxid aus Mangan(I)tricarbonyl-Komplexen im Vordergrund. Die oktaedrische Koordinationssph{\"a}re des Metallzentrums wurde dabei durch verschiedene faciale tridentate Liganden komplettiert, welche außerdem eine einfache und modulare Verkn{\"u}pfung mit biologischen Tr{\"a}ger-molek{\"u}len erm{\"o}glichen sollten. Als Chelatoren wurden Derivate von N,N-Bis(pyridin-2-ylmethyl)amin (bpa) ausgew{\"a}hlt, in denen das zentrale Stickstoffatom mit Alkylaminen unterschiedlicher Kettenl{\"a}nge funktionalisiert ist, welche {\"u}ber Amid-Bindungen mit Carboxylat-modifizierten Tr{\"a}germolek{\"u}len verkn{\"u}pft werden k{\"o}nnen. Diesen bpa-Liganden sollte ein neuartiges Ligandensystem auf der Basis von N-(Phenanthridin-6-ylmethyl)-N-(chinolin-2-ylmethyl)ethan-1,2-diamin (pqen) gegen{\"u}bergestellt werden, in denen die Phenanthridin-Gruppe interessante photophysikalische und photochemische Eigenschaften erwarten l{\"a}sst. Die CO-releasing molecules sollten zudem mit den isostrukturellen Rhenium(I)tricarbonyl-Komplexen verglichen werden, die als Marker f{\"u}r die Fluoreszenz-mikroskopie dienen.},
  subject      = {Metallcarbonyle},
  language  = {de}
}
@article{WobserSchummerAppenzelleretal.2022,
  author    = {Wobser, Marion and Schummer, Patrick and Appenzeller, Silke and Kneitz, Hermann and Roth, Sabine and Goebeler, Matthias and Geissinger, Eva and Rosenwald, Andreas and Maurus, Katja},
  title     = {Panel sequencing of primary cutaneous B-cell lymphoma},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {21},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14215274},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290330},
  year      = {2022},
  abstract  = {Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin's lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhibiting a low propensity for systemic dissemination or fatal outcome. Up to now, only few studies have investigated underlying molecular alterations of PCFBCL with respect to somatic mutations. Objectives: Our aim was to gain deeper insight into the pathogenesis of PCFBCL and to delineate discriminatory molecular features of this lymphoma subtype. Methods: We performed hybridization-based panel sequencing of 40 lymphoma-associated genes of 10 cases of well-characterized PCFBCL. In addition, we included two further ambiguous cases of atypical B-cell-rich lymphoid infiltrate/B-cell lymphoma of the skin for which definite subtype attribution had not been possible by routine investigations. Results: In 10 out of 12 analyzed cases, we identified genetic alterations within 15 of the selected 40 target genes. The most frequently detected alterations in PCFBCL affected the TNFRSF14, CREBBP, STAT6 and TP53 genes. Our analysis unrevealed novel mutations of the BCL2 gene in PCFBCL. All patients exhibited an indolent clinical course. Both the included arbitrary cases of atypical B-cell-rich cutaneous infiltrates showed somatic mutations within the FAS gene. As these mutations have previously been designated as subtype-specific recurrent alterations in primary cutaneous marginal zone lymphoma (PCMZL), we finally favored the diagnosis of PCMZL in these two cases based on these molecular findings. Conclusions: To conclude, our molecular data support that PCFBCL shows distinct somatic mutations which may aid to differentiate PCFBCL from pseudo-lymphoma as well as from other indolent and aggressive cutaneous B-cell lymphomas. While the detected genetic alterations of PCFBCL did not turn out to harbor any prognostic value in our cohort, our molecular data may add adjunctive discriminatory features for diagnostic purposes on a molecular level.},
  language  = {en}
}
@article{GuthHueserRothetal.2021,
  author    = {Guth, Sabine and H{\"u}ser, Stephanie and Roth, Angelika and Degen, Gisela and Diel, Patrick and Edlund, Karolina and Eisenbrand, Gerhard and Engel, Karl-Heinz and Epe, Bernd and Grune, Tilman and Heinz, Volker and Henle, Thomas and Humpf, Hans-Ulrich and J{\"a}ger, Henry and Joost, Hans-Georg and Kulling, Sabine E. and Lampen, Alfonso and Mally, Angela and Marchan, Rosemarie and Marko, Doris and M{\"u}hle, Eva and Nitsche, Michael A. and R{\"o}hrdanz, Elke and Stadler, Richard and van Thriel, Christoph and Vieths, Stefan and Vogel, Rudi F. and Wascher, Edmund and Watzl, Carsten and N{\"o}thlings, Ute and Hengstler, Jan G.},
  title     = {Contribution to the ongoing discussion on fluoride toxicity},
  series = {Archives of Toxicology},
  volume    = {95},
  journal   = {Archives of Toxicology},
  number    = {7},
  issn      = {0340-5761},
  doi       = {10.1007/s00204-021-03072-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-307161},
  pages     = {2571-2587},
  year      = {2021},
  abstract  = {Since the addition of fluoride to drinking water in the 1940s, there have been frequent and sometimes heated discussions regarding its benefits and risks. In a recently published review, we addressed the question if current exposure levels in Europe represent a risk to human health. This review was discussed in an editorial asking why we did not calculate benchmark doses (BMD) of fluoride neurotoxicity for humans. Here, we address the question, why it is problematic to calculate BMDs based on the currently available data. Briefly, the conclusions of the available studies are not homogeneous, reporting negative as well as positive results; moreover, the positive studies lack control of confounding factors such as the influence of well-known neurotoxicants. We also discuss the limitations of several further epidemiological studies that did not meet the inclusion criteria of our review. Finally, it is important to not only focus on epidemiological studies. Rather, risk analysis should consider all available data, including epidemiological, animal, as well as in vitro studies. Despite remaining uncertainties, the totality of evidence does not support the notion that fluoride should be considered a human developmental neurotoxicant at current exposure levels in European countries.},
  language  = {en}
}